Navigation Links
VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to Speak at the International Canine Sports Medicine Symposium
Date:1/5/2016

VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to Speak at the International Canine Sports Medicine Symposium during the North American Veterinary Conference.

Robert Harman, DVM, Founder and CEO of Regenerative Veterinary Medicine Company VetStem Biopharma, Inc. is scheduled to speak at the International Canine Sports Medicine Symposium during the North American Veterinary Conference in Orlando, Florida January 16-20, 2016. Dr. Harman is scheduled to speak on the second day of the conference, Sunday, January 17 in the Sarasota Room at the Gaylord Palms Hotel beginning at 10:55am.

In his presentation titled “Practical Regenerative Medicine Protocols for the Canine Athlete” Dr. Harman will discuss how Regenerative Medicine can be used in the treatment of acute and chronic injuries in the canine athlete. He pulls from his biotechnology and veterinary experience to help VetStem perfect the clinical application of stem cell therapy for various types of injuries, illnesses, and other healing-promoting applications. VetStem is leading in the development for regenerative medicine in the veterinary field, with over 11,000 animals treated in the last 12 years.

This year International Canine Sports Medicine Symposium is taking place during the North American Veterinary Conference in Orlando, Florida. All those who are attending the NAVC will also be allowed to attend the two day session of the International Canine Sports Medicine Symposium. The ICSMS is hosted by the University of Florida’s Comparative Orthopaedics and Biomechanics Laboratory. The chair for the ICSMS is Daniel D. Lewis, DVM, Diplomate ACVS-Professor, Small Animal Surgery, with Kristin Kirkby Shaw, DVM, Diplomate ACVS and Justin Shmalberg, DVM, Diplomate ACVN-Clinical Asst. Professor, Integrative Medicine as co-chairs.

VetStem first pioneered adipose derived stem cell therapy for use in horses for tendon injuries, as an alternative to euthanasia. Just two years after the first horse was treated, VetStem treated the first cat and dog. In 2007 the first peer reviewed, randomized, double-blinded, placebo controlled, multi-center study was published showing intra-articular injection of autologous adipose derived stem cells in the hip joint of a dog decreased patient discomfort and increased patient functional ability. That same year VetStem brought to market the Genesis Platelet Rich Plasma concentration system, as well as the first formal small animal stem cell credentialing course. In 2015, VetStem (now VetStem Biopharma) has announced the successful completion of a pilot efficacy study for allogeneic stem cell therapy (90 dogs, multi-center, blinded, placebo controlled) in support of an FDA INAD. Primary end point was statistically significant. The study has been submitted for peer reviewed publication. VetStem also entered into a distribution and clinical research agreement with Pall LifeSciences, including exclusive distribution rights in the US and Canada on V-PET™ platelet enhancement therapy system. V-PET™ is the only veterinary platelet therapy system supported by JAVMA peer reviewed publication of a multi center, double-blinded, randomized study in dogs.

About VetStem Biopharma

VetStem Biopharma is a veterinarian lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 12 years and 11,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.

Read the full story at http://www.prweb.com/releases/2016/01/prweb13146981.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. Peak Performance Veterinary Group and VetStem Biopharma, Announce Educational and Clinical Partnership in Support of Local Area Veterinarians
2. VetStem Biopharma and PALL Life Sciences announce a clinical research/technology distribution agreement for Pall’s Veterinary Platelet Enhancement Therapy system V-PET™
3. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to Present at Third Annual Clinical and Surgical Translation of Stem Cells
4. Advanced Care Veterinary Services is Now Offering Stem Cell Therapy for Dogs and Cats in Conjunction with VetStem Biopharma
5. VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease
6. VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015
7. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to be a Guest Speaker at MSC 2015 Adult Stem Cell Therapy & Regenerative Medicine Conference
8. VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product
9. VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour
10. VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center.
11. VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2018)... ... September 27, 2018 , ... Global molecular diagnostics company, ... Holotype HLA and other Omixon products will be featured among nine posters produced ... Histocompatibility and Immunogenetics (ASHI) in Baltimore, MD. Additionally, Omixon’s Lunch Symposium ...
(Date:9/22/2018)... ... September 20, 2018 , ... ... to announce a strategic venture. The synergistic combination of Predicine’s GeneRADAR molecular ... and comprehensive biomarker profiling to empower clinical trials in the immuno-oncology (IO) ...
(Date:9/22/2018)... ... September 21, 2018 , ... ... function, development, and pathogenesis requires tools that can rapidly and consistently quantify ... Ion Beam Imaging by Time-Of-Flight (MIBI-TOF) detects elements from hydrogen to uranium, ...
(Date:9/15/2018)... ... September 14, 2018 , ... Nationally recognized public accounting and consulting firm ... Managing Partner of the Firm’s Nashville practice, on her appointment to Launch Tennessee’s ... was named Managing Partner of the Firm’s Nashville practice in December 2017 . ...
Breaking Biology Technology:
(Date:10/16/2018)... ... October 16, 2018 , ... ... development, announces a new publication titled, “ Graphene-based Biosensor for On-Chip Detection of ... describes Agile R100 as a “new portable digital device for biosensing… that can ...
(Date:10/11/2018)... (PRWEB) , ... October 09, 2018 , ... ... unique role in helping market-ready technologies expedite their path to health system adoption ... gain full EHR interoperability across all major EHR applications, enabling them to focus ...
(Date:10/11/2018)... ... 11, 2018 , ... ODSC Europe 2018 - one of Open Data ... the event from September 19-22. , As Europe’s largest applied data science conference, ... and 4 days. Attendees were given key insights and hands-on training in ...
Breaking Biology News(10 mins):